Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes

References

• American Diabetes Association Standards of medical care in diabetes – 2012 Diabetes Care 2012 35 Suppl 1 S11 S63 22187469
   PubMed Web of Science ®Google Scholar
• Braga MF Casanova A Teoh H Diabetes Registry to Improve Vascular Events [DRIVE] Investigators Poor achievement of guidelines – recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study Int J Clin Pract 2012 66 5 457 464 22452524
   PubMed Web of Science ®Google Scholar
• Vouri SM Shaw RF Waterbury NV Egge JA Alexander B Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes J Manag Care Pharm 2011 17 4 304 312 21534641
   PubMed Web of Science ®Google Scholar
• Neumiller JJ Wood L Campbell RK Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus Pharmacotherapy 2010 30 5 463 484 20411998
   PubMed Web of Science ®Google Scholar
• Phillips LK Prins JB Update on incretin hormones Ann N Y Acad Sci 2011 1243 E55 E74 22545749
   PubMed Web of Science ®Google Scholar
• Matteucci E Giampietro O Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme Curr Med Chem 2009 16 23 2943 2951 19689275
   PubMed Web of Science ®Google Scholar
• Matteucci E Giampietro O Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety Curr Med Chem 2011 18 31 4753 4760 21919850
   PubMed Web of Science ®Google Scholar
• Rizos EC Ntzani EE Papanas N Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review Curr Vasc Pharmacol 6 22 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Kutoh E Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series J Med Case Rep 2011 5 117 21443773
   PubMedGoogle Scholar
• Ellis SL Moser EG Snell-Bergeon JK Rodionova AS Hazenfield RM Garg SK Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial Diabet Med 2011 28 10 1176 1181 21923696
   PubMed Web of Science ®Google Scholar
• George P McCrimmon RJ Potential role of non-insulin adjunct therapy in type 1 diabetes Diabet Med 7 18 2012 [Epub ahead of print.]
   Google Scholar
• Dhillon S Sitagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2010 70 4 489 512 20205490
   PubMed Web of Science ®Google Scholar
• Chwieduk CM Sitagliptin/metformin fixed-dose combination in patients with type 2 diabetes mellitus Drugs 2011 71 3 349 361 21319871
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Engel SS Round E Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 2010 10 7 20412573
   PubMed Web of Science ®Google Scholar
• Arnolds S Dellweg S Clair J Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study Diabetes Care 2010 33 7 1509 1515 20357372
   PubMed Web of Science ®Google Scholar
• Monami M Lamanna C Desideri CM Mannucci E DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv Ther 2012 29 1 14 25 22215383
   PubMed Web of Science ®Google Scholar
• Gin H Roudaut MF Vergnot V Baillet L Rigalleau V Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients Diabetes Metab 2003 29 5 505 508 14631327
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Rosenstock J Yki-Järvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 2 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Bosi E Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 2010 95 6 2607 2609 20525907
   PubMed Web of Science ®Google Scholar
• Rother KI Spain LM Wesley RA Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 2009 32 12 2251 2257 19808924
   PubMed Web of Science ®Google Scholar
• Foley JE Ligueros-Saylan M He YL Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes Horm Metab Res 2008 40 10 727 730 18597213
   PubMed Web of Science ®Google Scholar
• Boschmann M Engeli S Dobberstein K Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients J Clin Endocrinol Metab 2009 94 3 846 852 19088168
   PubMed Web of Science ®Google Scholar
• Vella S Buetow L Royle P Livingstone S Colhoun HM Petrie JR The use of metformin in type 1 diabetes: a systematic review of efficacy Diabetologia 2010 53 5 809 820 20057994
   PubMed Web of Science ®Google Scholar
• Khan AS McLoughney CR Ahmed AB The effect of metformin on blood glucose control in overweight patients with type 1 diabetes Diabet Med 2006 23 10 1079 1084 16978371
   PubMed Web of Science ®Google Scholar
• Lund SS Tarnow L Astrup AS Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes Diabetes Obes Metab 2009 11 10 966 977 19558610
   PubMed Web of Science ®Google Scholar
• True MW Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine J Diabetes Sci Technol 2009 3 4 743 747 20144323
   PubMedGoogle Scholar
• Cohen RM Holmes YR Chenier TC Joiner CH Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy Diabetes Care 2003 26 1 163 167 12502674
   PubMed Web of Science ®Google Scholar